

# Siqing Fu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3321238/publications.pdf>

Version: 2024-02-01

171  
papers

7,947  
citations

53794

45  
h-index

60623

81  
g-index

177  
all docs

177  
docs citations

177  
times ranked

12627  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.   | 7.0  | 458       |
| 2  | PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.  | 1.6  | 414       |
| 3  | <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.  | 4.1  | 311       |
| 4  | <i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.  | 0.9  | 262       |
| 5  | Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.  | 7.0  | 261       |
| 6  | Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. <i>Cell Reports</i> , 2014, 6, 377-387.   | 6.4  | 210       |
| 7  | Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.   | 0.9  | 203       |
| 8  | Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.                        | 9.4  | 192       |
| 9  | Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. <i>Clinical Cancer Research</i> , 2014, 20, 4827-4836.  | 7.0  | 186       |
| 10 | Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2625-2631.   | 7.0  | 184       |
| 11 | MABp1, a first-in-class true human antibody targeting interleukin-1 $\beta$ in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2014, 15, 656-666.                | 10.7 | 178       |
| 12 | PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.  | 2.5  | 174       |
| 13 | Phase 1b study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. <i>Cancer</i> , 2011, 117, 1661-1669. | 4.1  | 156       |
| 14 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.  | 2.6  | 149       |
| 15 | Development of curcumin as an epigenetic agent. <i>Cancer</i> , 2010, 116, 4670-4676.  | 4.1  | 146       |
| 16 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.                           | 7.0  | 127       |
| 17 | Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.   |      | 114       |
| 18 | Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.  | 3.0  | 107       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.   | 1.8 | 96        |
| 20 | Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.  | 2.6 | 90        |
| 21 | Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.   | 4.1 | 88        |
| 22 | Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.   | 1.8 | 86        |
| 23 | Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy. <i>Cancer Research</i> , 2012, 72, 4616-4621.  | 0.9 | 85        |
| 24 | PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.  | 1.8 | 79        |
| 25 | Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. <i>Clinical Cancer Research</i> , 2012, 18, 2922-2929.  | 7.0 | 78        |
| 26 | <i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.                                   | 4.1 | 78        |
| 27 | Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. <i>Clinical Cancer Research</i> , 2012, 18, 5796-5805. | 7.0 | 77        |
| 28 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 47-53.   | 1.4 | 74        |
| 29 | <i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.  | 4.1 | 73        |
| 30 | Weekly <i>mTOR</i> -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2013, 19, 5474-5484.  | 7.0 | 72        |
| 31 | Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1221-1225.   | 4.1 | 70        |
| 32 | Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.  | 7.0 | 70        |
| 33 | Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2483-2494.  | 4.1 | 67        |
| 34 | Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 4801-4810.                             | 7.0 | 63        |
| 35 | Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.   | 2.6 | 63        |
| 36 | Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. <i>Oncologist</i> , 2011, 16, 1292-1298.   | 3.7 | 60        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.   |     | 58        |
| 38 | Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015, 26, 1012-1018.    | 1.2 | 56        |
| 39 | Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. <i>Oncotarget</i> , 2014, 5, 2349-2354.                                     | 1.8 | 54        |
| 40 | Prevalence of complementary medicine use in a phase 1 clinical trials program. <i>Cancer</i> , 2011, 117, 5142-5150.   | 4.1 | 53        |
| 41 | Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014, 5, 11168-11179.   | 1.8 | 53        |
| 42 | Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2013, 31, 1192-1200.                          | 2.6 | 51        |
| 43 | Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 177.e1-177.e9.    | 1.3 | 50        |
| 44 | Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for earlyâ€phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.         | 4.1 | 50        |
| 45 | Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.     | 7.0 | 50        |
| 46 | Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.   | 7.0 | 50        |
| 47 | Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 495-501. | 2.3 | 46        |
| 48 | A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 407-418.                   | 2.3 | 46        |
| 49 | <i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.  | 1.8 | 45        |
| 50 | KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. <i>PLoS ONE</i> , 2012, 7, e38033.                      | 2.5 | 44        |
| 51 | Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.                                | 1.8 | 44        |
| 52 | Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015, 15, 713.                               | 2.6 | 43        |
| 53 | Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 741-751.   | 4.1 | 43        |
| 54 | Safety, pharmacokinetics, and activity of EZNâ€2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. <i>Cancer</i> , 2012, 118, 6144-6151.                          | 4.1 | 42        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.   | 4.1  | 42        |
| 56 | Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021, 26, 588-596.   | 3.7  | 42        |
| 57 | Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.  | 1.8  | 41        |
| 58 | Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014, 5, 3029-3038.  | 1.8  | 40        |
| 59 | Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 728-738.   | 2.4  | 38        |
| 60 | Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1307-1317.   | 3.4  | 36        |
| 61 | Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019, 12, 145.   | 17.0 | 35        |
| 62 | Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 973-977.  | 2.3  | 34        |
| 63 | Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2167-2175. | 4.1  | 33        |
| 64 | Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 671-676.  | 4.1  | 33        |
| 65 | Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013, 4, 118-127.   | 1.8  | 33        |
| 66 | Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3175-3184.                       | 4.1  | 31        |
| 67 | Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014, 32, 465-472.   | 2.6  | 31        |
| 68 | Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase I trials. <i>Oncotarget</i> , 2013, 4, 153-162.   | 1.8  | 31        |
| 69 | Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy. <i>Nutrition and Cancer</i> , 2012, 64, 206-217.                             | 2.0  | 29        |
| 70 | Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. <i>Clinical Breast Cancer</i> , 2014, 14, 468-474.  | 2.4  | 29        |
| 71 | Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018, 120, 137-141.   | 2.0  | 29        |
| 72 | Outcome Analyses After the First Admission to an Intensive Care Unit in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2011, 29, 3547-3552.                                       | 1.6  | 28        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.                                       | 6.4 | 28        |
| 74 | Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014, 5, 1846-1855.  | 1.8 | 28        |
| 75 | Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.                            | 4.1 | 27        |
| 76 | Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk <i>TP53</i> Mutation. <i>Clinical Cancer Research</i> , 2017, 23, 6541-6554.               | 7.0 | 27        |
| 77 | <i>MET</i> aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014, 5, 1837-1845.   | 1.8 | 27        |
| 78 | Clinical application of oxaliplatin in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1717-1732.  | 2.5 | 26        |
| 79 | A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010, 116, 4086-4094. | 4.1 | 26        |
| 80 | Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. <i>Supportive Care in Cancer</i> , 2015, 23, 2649-2654.   | 2.2 | 26        |
| 81 | Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 869-874.   | 2.3 | 26        |
| 82 | First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .   | 5.0 | 26        |
| 83 | Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2012, 30, 2891-2896.  | 1.6 | 25        |
| 84 | A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 177-186.   | 2.6 | 25        |
| 85 | MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. <i>Oncoscience</i> , 2013, 1, 5-13.  | 2.2 | 25        |
| 86 | Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021, 11, 5847.  | 3.3 | 24        |
| 87 | Germline <i>PTPRD</i> Mutations in Ewing Sarcoma: Biologic and Clinical Implications. <i>Oncotarget</i> , 2013, 4, 884-889.  | 1.8 | 24        |
| 88 | A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. <i>Oncotarget</i> , 2015, 6, 18693-18706.  | 1.8 | 24        |
| 89 | Targeting Aurora kinases in ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 77-85.  | 3.4 | 23        |
| 90 | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. <i>Frontiers in Oncology</i> , 2013, 3, 58.  | 2.8 | 23        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016, 7, 23227-23238.   | 1.8 | 23        |
| 92  | Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 247-253.  | 2.3 | 22        |
| 93  | Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin- Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1300-1307.  | 4.1 | 22        |
| 94  | Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 616-626.  | 2.6 | 22        |
| 95  | Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. <i>Oncoscience</i> , 2014, 1, 540-549.  | 2.2 | 22        |
| 96  | Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.   | 3.3 | 21        |
| 97  | Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit. <i>Oncologist</i> , 2013, 18, 1315-1320.   | 3.7 | 20        |
| 98  | Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.   | 2.8 | 20        |
| 99  | Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021, 124, 1533-1539.   | 6.4 | 20        |
| 100 | The changing face of Phase 1 cancer clinical trials. <i>Cancer</i> , 2009, 115, 1592-1597.   | 4.1 | 19        |
| 101 | MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e19-e26.  | 1.9 | 18        |
| 102 | Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2568-2577.  | 1.6 | 18        |
| 103 | Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1087-1093. | 2.3 | 17        |
| 104 | Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.   | 2.6 | 17        |
| 105 | Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. <i>Oncotarget</i> , 2013, 4, 772-784.                    | 1.8 | 16        |
| 106 | Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 4031-4037.                               | 7.0 | 15        |
| 107 | Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .  | 3.0 | 15        |
| 108 | Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 279-286.   | 2.6 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. <i>Cancer Biology and Therapy</i> , 2012, 13, 1034-1041.  | 3.4 | 13        |
| 110 | Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 389-397.   | 2.3 | 13        |
| 111 | Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. <i>Clinical Epigenetics</i> , 2015, 7, 29.   | 4.1 | 13        |
| 112 | Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.                                   | 4.3 | 13        |
| 113 | Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. <i>Cancer Medicine</i> , 2022, 11, 340-347.   | 2.8 | 13        |
| 114 | Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response. <i>Oncologist</i> , 2014, 19, 426-428.   | 3.7 | 12        |
| 115 | Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015, 33, 700-709.   | 2.6 | 12        |
| 116 | Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.   | 3.3 | 12        |
| 117 | Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.   | 5.4 | 12        |
| 118 | Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 10.  | 3.6 | 11        |
| 119 | The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. <i>Oncologist</i> , 2015, 20, 737-741.                          | 3.7 | 11        |
| 120 | Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.  |     | 11        |
| 121 | Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.   | 5.0 | 11        |
| 122 | Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014, 5, 3871-3879.  | 1.8 | 11        |
| 123 | Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.   | 7.0 | 10        |
| 124 | Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2017, 35, 59-67.   | 2.6 | 10        |
| 125 | Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.   | 3.3 | 10        |
| 126 | Use of Retroviral Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62<br>Anderson Cancer Center. <i>Human Gene Therapy</i> , 1993, 4, 821-834. | 2.7 | 10        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. <i>Gynecologic Oncology</i> , 2007, 106, 375-380.   | 1.4 | 9         |
| 128 | Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.   | 1.8 | 9         |
| 129 | Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015, 6, 28453-28462.  | 1.8 | 9         |
| 130 | Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.  | 1.8 | 9         |
| 131 | Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 367.e1-367.e6.  | 1.3 | 8         |
| 132 | Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2010, 9, 311-314.              | 2.3 | 8         |
| 133 | Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 154-159.  | 2.6 | 8         |
| 134 | Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.   | 2.6 | 8         |
| 135 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 15-30.  | 4.1 | 8         |
| 136 | Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 11019-11019.   | 1.6 | 8         |
| 137 | Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 563-572. | 0.6 | 8         |
| 138 | Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. <i>Anticancer Research</i> , 2014, 34, 2349-55.   | 1.1 | 8         |
| 139 | Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. <i>Investigational New Drugs</i> , 2015, 33, 911-920.   | 2.6 | 7         |
| 140 | Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 575-581.                                      | 2.3 | 7         |
| 141 | Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017, 140, 208-215.   | 5.1 | 7         |
| 142 | Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.  | 6.4 | 7         |
| 143 | Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.  | 3.4 | 7         |
| 144 | Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. <i>Scientific Reports</i> , 2022, 12, .  | 3.3 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest. <i>Pharmaceutical Research</i> , 2008, 25, 2272-2282.  | 3.5 | 6         |
| 146 | Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.   | 2.3 | 6         |
| 147 | Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014, 5, 8937-8946.  | 1.8 | 6         |
| 148 | Update on Aurora Kinase Inhibitors in Gynecologic Malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 162-177.   | 1.6 | 5         |
| 149 | Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1097-1102.   | 2.3 | 5         |
| 150 | A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 877-885. | 2.3 | 5         |
| 151 | Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor <sup>+</sup> positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.  | 7.0 | 5         |
| 152 | Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.  | 3.7 | 5         |
| 153 | Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 45-52.  | 1.4 | 5         |
| 154 | Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017, 8, 33796-33806.  | 1.8 | 5         |
| 155 | A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. <i>Scientific Reports</i> , 2021, 11, 22355.  | 3.3 | 5         |
| 156 | Retreatment after Secondary Resistance or Mixed Response: A Pilot Study. <i>Oncology</i> , 2013, 85, 350-355.   | 1.9 | 4         |
| 157 | Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 194-203.   | 4.9 | 4         |
| 158 | Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 357-364.   | 2.3 | 4         |
| 159 | Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.  | 7.0 | 4         |
| 160 | Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. <i>Investigational New Drugs</i> , 2014, 32, 717-722.                                     | 2.6 | 3         |
| 161 | Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017, 92, 14-20.  | 1.9 | 3         |
| 162 | Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1204-1215.      | 2.0 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. <i>Investigational New Drugs</i> , 2022, 40, 124-133.          | 2.6 | 2         |
| 164 | Abstract B134: PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. , 2009, , .  |     | 2         |
| 165 | Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012, 59, 960-4.   | 0.5 | 2         |
| 166 | Molecular approaches to the diagnosis and treatment of cancer. <i>Stem Cells</i> , 1993, 11, 129-130.  | 3.2 | 1         |
| 167 | Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24. | 1.9 | 1         |
| 168 | Genetic Therapy of Human Neoplastic Disease. <i>Stem Cells and Development</i> , 1993, 2, 373-375.   | 1.0 | 0         |
| 169 | Proteomics in Gynecologic Malignancies. <i>American Journal of Cancer</i> , 2006, 5, 299-317.  | 0.4 | 0         |
| 170 | Reply to M. Rouanne et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 818-818.  | 1.6 | 0         |
| 171 | Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.  | 1.8 | 0         |